Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.

Journal of the Chinese Medical Association : JCMA - 1 Mar 2007

Hsu Hui-Chi

Abstract excerpt

The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The hematopoietic progenitor cells of patients with polycythemia vera (PV) or essential thrombocythemia (ET) are characterized by hypersensitivity to hematopoietic growth factors and formation of endogenous erythroid colonies. Recently, 4 groups reported almost simultaneously Janus kinase 2 (JAK2) V617F mutation in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Disease
Share to JAK2 gene
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 17389152
DOI: 10.1016/S1726-4901(09)70337-5

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.PMID 17389152Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.Semantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

The JAK2 mutation.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

Myeloproliferative disordersSemantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasms.Semantic proximity Read ↗

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.Semantic proximity Read ↗

JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.